BR112014031204A2 - derivados deuterados de ruxolitinib - Google Patents

derivados deuterados de ruxolitinib

Info

Publication number
BR112014031204A2
BR112014031204A2 BR112014031204A BR112014031204A BR112014031204A2 BR 112014031204 A2 BR112014031204 A2 BR 112014031204A2 BR 112014031204 A BR112014031204 A BR 112014031204A BR 112014031204 A BR112014031204 A BR 112014031204A BR 112014031204 A2 BR112014031204 A2 BR 112014031204A2
Authority
BR
Brazil
Prior art keywords
ruxolitinib
deuterated derivatives
compound
formula
deuterated
Prior art date
Application number
BR112014031204A
Other languages
English (en)
Inventor
J Morgan Adam
Pandya Bhaumik
robert silverman I
F Liu Julie
L Harbeson Scott
Original Assignee
Concert Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48699982&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014031204(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Concert Pharmaceuticals Inc filed Critical Concert Pharmaceuticals Inc
Priority to BR122023027277-3A priority Critical patent/BR122023027277A2/pt
Publication of BR112014031204A2 publication Critical patent/BR112014031204A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Abstract

resumo patente de invenção: "derivados deuterados de ruxolitinib". a presente invenção em uma modalidade refere-se a um composto da fórmula a: fórmula a, ou um sal farmaceuticamente aceitável do mesmo; composições farmacêuticas que compreendem o composto; e processos de tratamento das indicações divulgadas aqui.
BR112014031204A 2012-06-15 2013-06-14 derivados deuterados de ruxolitinib BR112014031204A2 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122023027277-3A BR122023027277A2 (pt) 2012-06-15 2013-06-14 Derivados deuterados de ruxolitinib e composição farmacêutica

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261660428P 2012-06-15 2012-06-15
US201261678795P 2012-08-02 2012-08-02
PCT/US2013/045919 WO2013188783A1 (en) 2012-06-15 2013-06-14 Deuterated derivatives of ruxolitinib

Publications (1)

Publication Number Publication Date
BR112014031204A2 true BR112014031204A2 (pt) 2017-06-27

Family

ID=48699982

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112014031204A BR112014031204A2 (pt) 2012-06-15 2013-06-14 derivados deuterados de ruxolitinib
BR122023027277-3A BR122023027277A2 (pt) 2012-06-15 2013-06-14 Derivados deuterados de ruxolitinib e composição farmacêutica

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR122023027277-3A BR122023027277A2 (pt) 2012-06-15 2013-06-14 Derivados deuterados de ruxolitinib e composição farmacêutica

Country Status (11)

Country Link
EP (3) EP3450434B1 (pt)
AU (3) AU2013274030B2 (pt)
BR (2) BR112014031204A2 (pt)
CA (1) CA2876306C (pt)
DK (1) DK3450434T3 (pt)
EA (1) EA201492287A1 (pt)
ES (1) ES2867048T3 (pt)
IN (1) IN2014DN10670A (pt)
MX (1) MX360495B (pt)
PL (1) PL3450434T3 (pt)
WO (1) WO2013188783A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101391900B1 (ko) 2005-12-13 2014-05-02 인사이트 코포레이션 야누스 키나아제 억제제로서의 헤테로아릴 치환된 피롤로［2,3-ｂ］피리딘 및 피롤로［2,3-ｂ］피리미딘
SI3050882T1 (en) 2010-03-10 2018-06-29 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives, as inhibitors of JAK1
ES2560611T3 (es) 2011-06-20 2016-02-22 Incyte Holdings Corporation Derivados de fenil de azetidinilo, carboxamida de piridilo o pirazinilo como inhibidores de JAK
DK3450434T3 (da) 2012-06-15 2021-05-03 Concert Pharmaceuticals Inc Deutererede derivater af ruxolitinib
US20150197525A1 (en) 2012-06-15 2015-07-16 Concert Pharmaceuticals, Inc. Deuterated derivatives of ruxolitinib
UA120834C2 (uk) 2012-11-15 2020-02-25 Інсайт Холдінгс Корпорейшн Лікарські форми руксолітинібу зі сповільненим вивільненням
CN105579032A (zh) 2013-08-07 2016-05-11 因赛特公司 Jak1抑制剂的持续释放剂型
EP4233870A3 (en) 2014-05-28 2024-01-24 Onco Tracker, Inc. Anti-cancer effects of jak2 inhibitors in combination with thalidomide derivatives and glucocorticoids
MX2019006821A (es) * 2016-12-14 2019-10-21 Progenity Inc Tratamiento de una enfermedad del tracto gastrointestinal con un inhibidor de cinasa de janus (jak) y dispositivos.
WO2019113487A1 (en) * 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
US20220306636A1 (en) * 2019-02-06 2022-09-29 Concert Pharmaceuticals, Inc. Process for preparing enantiomerically enriched jak inhibitors
WO2021236139A1 (en) 2020-05-21 2021-11-25 Concert Pharmaceuticals, Inc. Novel deuterated jak inhibitor and uses thereof
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
WO2023018904A1 (en) 2021-08-11 2023-02-16 Concert Pharmaceuticals, Inc. Treatment of hair loss disorders with deuterated jak inhibitors
CA3228509A1 (en) 2021-08-12 2023-02-16 Sun Pharmaceutical Industries, Inc. Treatment of jak-inhibition-responsive disorders with prodrugs of jak inhibitors
CN117384163A (zh) * 2022-07-05 2024-01-12 盛世泰科生物医药技术(苏州)股份有限公司 一种含偕二氟基的化合物及其制备方法和用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5716981A (en) 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
GB9925962D0 (en) 1999-11-02 1999-12-29 Novartis Ag Organic compounds
RS83503A (en) 2001-05-03 2006-10-27 F. Hoffmann-La Roche Ag. Pharmaceutical dosage form of amorphous nelfinavir mesylate
EP1392262A1 (en) 2001-05-24 2004-03-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
BRPI0516170A (pt) 2004-09-29 2008-08-26 Cordis Corp formas de dosagens farmacêuticas estáveis e amorfas de compostos de rapamicina
KR101391900B1 (ko) * 2005-12-13 2014-05-02 인사이트 코포레이션 야누스 키나아제 억제제로서의 헤테로아릴 치환된 피롤로［2,3-ｂ］피리딘 및 피롤로［2,3-ｂ］피리미딘
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
JP2011510079A (ja) 2008-01-22 2011-03-31 コンサート ファーマシューティカルズ インコーポレイテッド ゲフィチニブ誘導体
JOP20190231A1 (ar) 2009-01-15 2017-06-16 Incyte Corp طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
DK3450434T3 (da) 2012-06-15 2021-05-03 Concert Pharmaceuticals Inc Deutererede derivater af ruxolitinib
UA120834C2 (uk) * 2012-11-15 2020-02-25 Інсайт Холдінгс Корпорейшн Лікарські форми руксолітинібу зі сповільненим вивільненням

Also Published As

Publication number Publication date
EP2861600A1 (en) 2015-04-22
BR122023027277A2 (pt) 2024-01-23
CA2876306A1 (en) 2013-12-19
IN2014DN10670A (pt) 2015-08-28
AU2016238877A1 (en) 2016-10-27
MX360495B (es) 2018-11-06
WO2013188783A8 (en) 2014-02-27
MX2014015185A (es) 2015-02-17
AU2018271227A1 (en) 2018-12-13
AU2016238877B2 (en) 2018-08-30
EP3882249A1 (en) 2021-09-22
EP3450434B1 (en) 2021-02-24
EA201492287A1 (ru) 2015-07-30
EP3450434A1 (en) 2019-03-06
PL3450434T3 (pl) 2021-10-04
AU2013274030B2 (en) 2016-07-07
ES2867048T3 (es) 2021-10-20
AU2018271227B2 (en) 2020-08-27
AU2013274030A1 (en) 2015-01-22
WO2013188783A1 (en) 2013-12-19
CA2876306C (en) 2024-02-20
DK3450434T3 (da) 2021-05-03

Similar Documents

Publication Publication Date Title
BR112014031204A2 (pt) derivados deuterados de ruxolitinib
BR112014026703A2 (pt) inibidores de dna-pk
BR112015000150A2 (pt) composições farmacêuticas dissuasoras de abuso de liberação controlada
BR112015003188A2 (pt) Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BR112015011497A2 (pt) composto, formulação farmacêutica, produto de combinação, e, método de tratamento de uma doença
BR112014006271A2 (pt) composições farmacêuticas
BR112015012197A2 (pt) terapia de combinação
BR112014031394A2 (pt) composições e métodos para absorção transmucosa
BR112014001600A2 (pt) composto inibidor do trajeto de sinalização notch
BR112014018879A8 (pt) Composto e composição farmacêutica e combinação compreendendo dito composto
BR112013005432A2 (pt) tratamento de doenças
BR112014024672A8 (pt) Composições farmacêuticas para terapia de combinação
BR112015014458A2 (pt) derivados de manose para o tratamento de infecções bacterianas
BR112015005117A2 (pt) métodos de tratamento da doença de alzheimer e suas composições farmacêuticas
MX2014009757A (es) Derivados de isoindolina, composiciones farmaceuticas que los contienen y su uso en terapia.
EA201500365A1 (ru) Комбинация регорафениба и ацетилсалициловой кислоты для лечения рака
BR112013010310A2 (pt) inibidores de acetil-coa carboxilase de lactama n1/n2
BR112015004501A2 (pt) derivado de ácido hialurônico tendo aminoácidos e grupos esterila introduzidos no mesmo
EA201201658A1 (ru) Производные пиперидина и их применение для лечения метаболических нарушений
BR112014005025A2 (pt) composição farmacêutica para uso no tratamento de uma doença neurodegenerativa
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112012031340A2 (pt) derivados de cianoquinolina
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
BR112013022213A2 (pt) administração parenteral de tapentadol
BR112015026967A8 (pt) fenoxietil di-hidro-1h-isoquinolina, seus usos, e composição farmacêutica

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122023011289-0 PROTOCOLO 870230048946 EM 07/06/2023 16:13.

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122023027277-3 PROTOCOLO 870230113514 EM 22/12/2023 13:59.

B25A Requested transfer of rights approved

Owner name: SUN PHARMACEUTICAL INDUSTRIES, INC. (US)